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Summary
 
MAGE
 
-type genes are expressed by many tumors of different histological types and not by
normal cells, except for male germline cells, which do not express major histocompatibility
complex (MHC) molecules. Therefore, the antigens encoded by 
 
MAGE
 
-type genes are strictly
tumor specific and common to many tumors. We describe here the identification of the first
 
MAGE
 
-encoded epitopes presented by histocompatibility leukocyte antigen (HLA) class II
molecules to CD4
 
1
 
 T lymphocytes. Monocyte-derived dendritic cells were loaded with a
MAGE-3 recombinant protein and used to stimulate autologous CD4
 
1
 
 T cells. We isolated
CD4
 
1
 
 T cell clones that recognized two different MAGE-3 epitopes, MAGE-3
 
114–127
 
 and
MAGE-3
 
121–134
 
,
 
 
 
both presented by the HLA-DR13 molecule, which is expressed in 20% of
Caucasians. The second epitope is also encoded by 
 
MAGE-1
 
,
 
 -2
 
,
 
 
 
and -
 
6
 
. Our procedure
should be applicable to other proteins for the identification of new tumor-specific antigens pre-
sented by HLA class II molecules. The knowledge of such antigens will be useful for evaluation
of the immune response of cancer patients immunized with proteins or with recombinant vi-
ruses carrying entire genes coding for tumor antigens. The use of antigenic peptides presented
by class II in addition to peptides presented by class I may also improve the efficacy of thera-
peutic antitumor vaccination.
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F
 
rom cultures of blood lymphocytes or tumor-infiltrat-
ing lymphocytes of cancer patients stimulated with au-
tologous tumor cells, it is possible to isolate CTLs that
show specificity for tumor cells (1, 2). These CTLs have
been used as tools to isolate genes that code for tumor anti-
gens, such as those of the 
 
MAGE
 
 gene family (3, 4). The
MAGE antigens are of particular interest for cancer immu-
notherapy because of their strict tumoral specificity and be-
cause they are shared by many tumors. 
 
MAGE
 
 genes are
activated in tumors of many different histological types.
They are silent in normal cells, except in testicular germ
cells, which do not express MHC class I molecules and are
therefore incapable of presenting antigens to CTLs (5, 6).
Other families of genes with the same pattern of expression
have been identified (7, 8). In addition to the genes identi-
fied with the approach involving antitumor CTLs, several
other 
 
MAGE
 
-type genes, i.e., genes expressed only in tu-
mors and in male germline cells, have been identified by
purely genetic approaches or by the use of antibodies
present in the sera of cancer patients (9–11). As a result,
there is now a large supply of sequences potentially coding
for tumor-specific shared antigens.
Among the 
 
MAGE
 
 genes, 
 
MAGE-3
 
 is one of the most
frequently expressed in tumors. For instance, it is expressed
in 76% of metastatic melanomas (12). Five antigenic pep-
tides presented by class I molecules have been identified in
the MAGE-3 protein. They are presented to CTLs by
HLA-A1, -A2 (two epitopes), -A24, and -B44 (12–17).
Some of these epitopes were identified as targets of CTL
clones obtained by stimulation of T lymphocytes with au- 
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tologous tumor cells. Others were identified by “reverse
immunology” approaches, based on the knowledge of gene
sequences and in vitro stimulation of lymphocytes of non-
cancerous individuals with candidate peptides considered
likely to bind to a given HLA. 
 
MAGE-3
 
 codes for a pro-
tein of 315 amino acids, and it is very likely that many
other peptides derived from MAGE-3 bind to various HLA
molecules and hence could be additional target antigens for
an antitumor CTL response.
So far, the identification of tumor antigens has focused
mainly on antigens recognized by CTLs, almost all of
which are CD8
 
1
 
, even though the importance of CD4
 
1
 
 T
cells in antitumor response has been demonstrated in nu-
merous animals models (18–21). Only a few examples of
antigens recognized by CD4
 
1
 
 T cells on human tumors
have been described. CD4
 
1
 
 T cells that were raised
 
 
 
in vitro
against a peptide centered on the fusion region of bcr-abl
were found to recognize HLA-DR4 leukemic blasts ex-
pressing bcr-abl (22). The same approach had been previ-
ously used to identify an epitope presented by HLA-DQ7
molecules in a mutated region of K-
 
ras
 
 (23). Antigenic
peptides encoded by the melanocyte differentiation pro-
teins tyrosinase and gp100 have also been identified (24–26).
No antigen presented by a class II molecule has yet been
reported for a 
 
MAGE-
 
type gene. In an attempt to charac-
terize such an antigen for 
 
MAGE-3
 
, we used monocyte-
derived dendritic cells loaded with a MAGE-3 recombinant
protein to stimulate autologous CD4
 
1
 
 T cells. We report
here the identification of MAGE-3 epitopes presented by
HLA-DR molecules.
 
Materials and Methods
 
Cell Lines, Media, and Reagents.
 
The EBV-transformed B
(EBV-B) cell lines and tumor cell line MZ2-MEL.43 were cul-
tured in IMDM (GIBCO BRL) supplemented with 10% FCS
(GIBCO BRL), 0.24 mM 
 
l
 
-asparagine, 0.55 mM 
 
l
 
-arginine, 1.5
mM 
 
l
 
-glutamine (AAG), 100 U/ml penicillin, and 100 
 
m
 
g/ml
streptomycin. The PhoenixAMPHO cell line (provided by Dr.
Nolan, Stanford University, Stanford, CA) is a high-titer ampho-
tropic retrovirus–producing cell line that was generated by stable
transfection of 293T cells with a Moloney GagPol-IRES-Lyt 2
construct with a Rous sarcoma virus (RSV) promoter and a
pPGK hygro selectable marker. These cells were then stably
transfected with the Moloney amphotropic envelope gene driven
by a CMV promoter and coselected with the diphtheria toxin
resistance gene (pHED-7). This producer cell line is helper
virus–free. PhoenixAMPHO cells were cultured in DMEM (Life
Technologies) supplemented with 10% heat-inactivated FCS,
2 mM 
 
l
 
-glutamine, and antibiotics.
Human recombinant IL-2 was purchased from Eurocetus, IL-7
from Genzyme, GM-CSF from Schering Plough, and TNF-
 
a
 
from R&D Systems. Human recombinant IL-4, IL-6, and IL-12
were produced in our laboratory.
 
MAGE-3 Protein.
 
The recombinant MAGE-3 protein was
produced by SmithKline Beecham Pharmaceuticals. The full-
length MAGE-3 sequence, preceded by the amino acid (aa)
 
1
 
 se-
 
quence MHHHHHHHGG, was engineered into a vector bear-
ing the pMB1 replicon and the PL short promoter. This vector
was used to transform 
 
Escherichia coli
 
 strain AR58 (27). Bacteria
were grown in LB medium containing 50 
 
m
 
g/ml kanamycin at
30
 
8
 
C. After heat induction, the MAGE-3 expression product be-
came detectable as a 46-kD band when assayed by Western blot
(SDS-PAGE 12.5%; revealed by a rabbit polyclonal antiserum to
MAGE-3). Protein purification was carried out at room tempera-
ture, and involved the following steps: cell lysis and centrifuga-
tion, repeated washing of the centrifugation pellet followed by
solubilization of the pellet containing MAGE-3, immobilized
metal ion affinity chromatography, anion exchange chromatog-
raphy, concentration, and dialysis. The resulting MAGE-3 pro-
tein was 
 
.
 
95% pure, as assessed by Coomassie blue staining.
 
Construction of pMFG-Ii.MAGE-3.
 
The plasmid IipSV51L,
containing a cDNA encoding the human invariant chain (Ii), was
provided by Dr. J. Pieters (Basel Institute for Immunology, Basel,
Switzerland). The MFG plasmid was provided by Dr. O. Danos
(Somatix Therapy Corp., Alameda, CA). The MFG retroviral
vector is derived from the Moloney murine leukemia virus,
which lacks a drug resistance marker and does not express any
other potential antigenic protein except for the inserted cDNA
(28). The cDNA encoding the NH
 
2
 
-terminal end (i.e., the cy-
toplasmic tail and the transmembrane region) of the human
(hu)-Ii polypeptide (residues 1–80) was amplified by PCR using
IipSV51L as the template. The following primers were used:
hu-Ii sense, 5
 
9
 
-TTT
 
CCATGG
 
ATGACCAGCGCGAC-3
 
9
 
, and
hu-Ii antisense, 5
 
9
 
-TTT
 
GGATCC
 
GGAAGCTTCATGCGCAG-
GTTC-3
 
9
 
 (the recognition sites for NcoI and BamHI are in ital-
ics). The PCR product was cloned into pCR2.1 and sequenced.
The NcoI-BamHI amplification product was cloned into pMFG
and opened with the enzymes NcoI and BamHI, resulting in
pMFG-Ii. A BglII recognition site, replacing the ATG codon and
in frame with the BamHI site at the 3
 
9
 
 end of the truncated
Ii-cDNA, was introduced at the 5
 
9
 
 end of the MAGE-3 cDNA
by PCR using the following primers: BglII sense, 5
 
9
 
-TTT
 
A-
GATCT
 
TGAGCAGAGGAGTCAGC-3
 
9
 
, and BglII antisense:
5
 
9
 
-CCC
 
AGATCT
 
TCACTCTTCCCCCTCTCTC-3
 
9
 
 (the rec-
ognition sites for BglII are in italics). The PCR product (BglII.
MAGE-3.BglII) was cloned into pCR2.1 and sequenced. The
recombinant plasmid, pMFG-Ii, was reopened with BamHI, and
the BglII.MAGE-3.BglII amplification product was ligated to the
compatible ends. Recombinant plasmids containing the MAGE-3
cDNA in frame and in the right orientation were identified by
restriction fragment analysis.
 
Production of High-titer Ii.MAGE-3–encoding Recombinant Retro-
virus.
 
The MAGE-3–encoding retroviral vector plasmid MFG-
Ii.MAGE-3 was introduced into the PhoenixAMPHO packaging
cells by transfection. The transfection procedure is a modification
of the calcium phosphate–mediated transfection protocol of Gra-
ham and Van der Eb (29). 24 h before transfection, PhoenixAM-
PHO cells were plated in cell growth medium in a 75-cm
 
2
 
 tissue
culture flask (Falcon; Becton Dickinson Labware). After adding
the cells, the flask was gently shaken forward and backward to
distribute cells evenly in the flask bottom. The cells were incu-
bated at 37
 
8
 
C and 5% CO
 
2
 
. At the time of transfection, when the
cells should have reached a confluence of 70–80%, the medium
was removed and replaced by 14 ml fresh PhoenixAMPHO cell
growth medium containing 25 mM chloroquine (Sigma). A
transfection cocktail was prepared in a 50-ml tube by adding 40 
 
m
 
g
retroviral vector plasmid DNA to water and diluting to 1,575 
 
m
 
l
final vol. To this DNA solution 225 
 
m
 
l of 2 M CaCl
 
2
 
 was added.
Then, 1,800 
 
m
 
l of 2
 
3
 
 HeBS (50 mM Hepes, 10 mM KCl, 12 mM
 
1
 
Abbreviations used in this paper:
 
 aa, amino acid(s); Ii, invariant chain(s). 
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dextrose, 280 mM NaCl, and 1.5 mM Na
 
2
 
HPO
 
4
 
 dissolved in dis-
tilled water, filtered through a 0.2-
 
m
 
m filter, and stored at
 
2
 
20
 
8
 
C) was added in drops to the DNA/CaCl
 
2
 
 solution by bub-
bling vigorously for 15 s with an automatic pipette. The DNA/
CaCl
 
2
 
/HeBS mix was added immediately in drops onto the cells,
and the flask was gently swirled to ensure uniform mixing of
DNA/CaPO
 
4
 
 particles. The cells were incubated at 37
 
8
 
C/5%
CO
 
2
 
 for 7–9 h, and the chloroquine-containing medium was
changed for fresh PhoenixAMPHO cell growth medium. Ap-
proximately 24 h before the harvest of the retroviral supernatant,
the PhoenixAMPHO medium was removed and gently replaced
by 9 ml of IMDM containing only 2.5% FCS. The retroviral su-
pernatant was harvested 48 h after transfection by removing the
medium from the cells and filtering through a 0.45-
 
m
 
m filter to
remove cell debris. After harvest and filtration, the virus-contain-
ing medium was kept on ice, aliquoted in appropriate volumes in
15-ml polypropylene tubes, and stored at 
 
2
 
80
 
8
 
C.
 
Retroviral Transduction of Cell Lines.
 
Target cells were resus-
pended in 60-mm tissue culture plates (Falcon) at a density of 10
 
6
 
cells in 4 ml of infection cocktail containing 50% viral superna-
tant in growth medium and 6 
 
m
 
g/ml of protamine sulfate. The
plates were centrifuged for 2 h at 32
 
8
 
C and 1,200 rpm, followed
by another 2 h of incubation in a humidified incubator at 37
 
8
 
C.
Cells were then transferred to 4 ml of growth medium. This
transduction cycle was carried out immediately after plating the
cells and was repeated at 24 and 48 h.
 
Dendritic Cells.
 
Blood cells were collected as buffy coat prep-
arations from hemochromatosis patients. PBMCs were isolated
by Lymphoprep (Nycomed Pharma) density gradient centrifuga-
tion. To generate autologous dendritic cells, PBMCs were de-
pleted from T lymphocytes by rosetting with sheep erythrocytes
(Bio Mérieux) treated with 2-aminoethylisothiouronium (Sigma).
The lymphocyte-depleted PBMCs were left to adhere for 2 h at
37
 
8
 
C in culture flasks (Falcon) at a density of 2 
 
3 
 
10
 
6
 
 cells/ml in
RPMI 1640 medium supplemented with AAG and 1% autolo-
gous plasma (hereafter referred to as complete RPMI medium).
Nonadherent cells were discarded, and adherent cells were cul-
tured in the presence of IL-4 (100 U/ml) and GM-CSF (100 ng/
ml) in complete RPMI medium. Cultures were fed on days 2 and
4 by replacing half of the medium with fresh medium plus IL-4
(100 U/ml) and GM-CSF (100 ng/ml). On day 5, the nonadher-
ent cell population was used as a source of enriched dendritic
cells.
 
CD4
 
1
 
 Responder T Cells.
 
Rosetted T cells were treated with
NH
 
4
 
Cl (160 mM) to lyse the sheep erythrocytes and washed.
CD4
 
1
 
 T lymphocytes were isolated from rosetted T cells by neg-
ative selection using an anti-CD8 mAb coupled to magnetic mi-
crobeads (Miltenyi Biotech) and by sorting through a MACS
 
®
 
, as
recommended by the manufacturer. The lymphocytes were fro-
zen and then thawed the day before the coculture with dendritic
cells.
 
Mixed Lymphocyte/Dendritic Cell Culture.
 
Autologous den-
dritic cells (5 
 
3 
 
10
 
5
 
/ml) were incubated at 37
 
8
 
C, 5% CO
 
2
 
 for
18–20 h in complete medium supplemented with IL-4 (100 U/
ml), GM-CSF (100 ng/ml), and TNF-a (1 ng/ml) in the pres-
ence of the recombinant MAGE-3 protein (20 mg/ml). Cells
were washed and added at 104 per round-bottomed microwell to
105 CD41 lymphocytes in 200 ml IMDM supplemented with
AAG and 10% human serum (hereafter referred to as complete
IMDM) in the presence of IL-6 (1,000 U/ml) and IL-12 (10 ng/
ml). The CD41 lymphocytes were restimulated on days 7, 14,
and 21 with autologous dendritic cells freshly loaded with the
MAGE-3 protein and were grown in complete IMDM supple-
mented with IL-2 (10 U/ml) and IL-7 (5 ng/ml). Due to the lim-
ited supply of dendritic cells for melanoma patient 7002, we used
only 6 3 103 dendritic cells instead of 104 and restimulations were
performed on days 10 and 20 instead of 7, 14, and 21. The mi-
crocultures containing proliferating CD41 T cells were assessed
on days 35–37 for their capacity to produce TNF and/or IFN-g
when stimulated with autologous EBV-B cells loaded with protein
MAGE-3. Autologous EBV-B cells were incubated for 18–20 h
in the presence of 20 mg/ml of protein MAGE-3, or OVA
(Sigma) as a negative control. Protein-pulsed EBV-B cells were
washed and distributed at 5,000 cells per round-bottomed mi-
crowell together with 2,500 CD41 T lymphocytes in 150 ml of
complete IMDM supplemented with IL-2 (25 U/ml). After 20 h,
the supernatant was collected and its TNF content was deter-
mined by testing its cytotoxic effect on WEHI-164 clone 13 cells
(30) in a MTT colorimetric assay (31, 32). IFN-g released in the
supernatant was measured by ELISA using reagents from
Medgenix Diagnostics-Biosource. Inhibition with mAbs W6/32
(anti–HLA class I) or 2B6 (anti–HLA-DR) was performed by ad-
dition of a 1:20 dilution of ascites during the experiment.
CD41 T Cell Clones. The microcultures that recognized
cells loaded with the MAGE-3 protein were cloned by limiting
dilution, using as stimulating cells either the autologous EBV-B
cell line loaded with the MAGE-3 protein or the autologous
EBV-B cell line transduced with a retrovirus encoding Ii.MAGE-3.
Allogeneic EBV-B cells (LG2-EBV) were added as feeder cells.
CD41 T cell clones were grown in complete IMDM supple-
mented with IL-2 (50 U/ml), IL-7 (5 ng/ml), and 0.5 mg/ml pu-
rified PHA (HA 16; Murex Diagnostics). The clones were sup-
plemented with fresh culture medium once a week and passaged
with feeder cells (1.5 3 106 allogeneic PBLs plus 5 3 105 LG2-
EBV per well in a 24-well plate) at 1–2-wk intervals. Occasion-
ally, clones were restimulated with 2 3 105 autologous EBV-B
cells transduced with Ii.MAGE-3 as stimulating cells and 106
LG2-EBV. Established CD41 T cell clones were then tested
for TNF and/or IFN-g production after stimulation with autolo-
gous EBV-B cells pulsed with protein MAGE-3 and MAGE-3–
derived peptides.
Recognition Assays with Peptides. Peptides were synthesized on
solid phase using F-moc for transient NH2-terminal protection
and were characterized using mass spectrometry. All peptides
were .80% pure, as indicated by analytical HPLC. Lyophilized
peptides were dissolved in DMSO and used at a concentration of
5 mg/ml. EBV-B cells were incubated for 2 h at 378C in the
presence of the different peptides, the indicated concentrations
representing their concentrations during the incubation step.
They were distributed at 5,000 cells per round-bottomed mi-
crowell together with 2,500 CD41 T lymphocytes in 150 ml of
complete IMDM supplemented with IL-2 (25 U/ml). Superna-
tants were harvested after 20 h and assessed for TNF and/or IFN-g
production. The results represent the average of duplicate or trip-
licate cultures.
Recognition Assays with Cell Lysates. The MAGE-3 cDNA se-
quence cloned into expression vector pCEP-4 was transiently
transfected into the 293-EBNA cell line by Lipofectamine®
(GIBCO BRL). In brief, 5 3 104 293-EBNA cells per flat-bot-
tomed microwell were transfected with pCEP4-MAGE-3 and 1 ml
of Lipofectamine® in Optimem medium (GIBCO BRL). After
24 h, transfected 293-EBNA cells were lysed in 50 ml of com-
plete RPMI medium by three cycles of rapid freeze–thawing.
Monocyte-derived dendritic cells expressing HLA-DR13 mole-
cules were then added (1.5 3 104 cells per well) to the lysates of
transfected 293-EBNA cells and kept at 378C for 24 h. The den-770 MAGE-3 Epitopes Presented by HLA Class II Molecules
dritic cells were then washed, and 2,500 CD41 lymphocytes
were added in 150 ml of complete IMDM supplemented with
IL-2 (25 U/ml). Supernatants were harvested after 20 h and as-
sessed for IFN-g production.
Results
Blood monocytes were cultured in medium supple-
mented with GM-CSF and IL-4 to favor their differentia-
tion into dendritic cells (Fig. 1). Autologous plasma was
used to avoid loading the dendritic cells with bovine or al-
logeneic proteins. After 5 d, the dendritic cells were incu-
bated overnight with 20 mg/ml of a MAGE-3 protein
produced in E. coli and with TNF-a to induce their matu-
ration. 96 microcultures were set up with 105 autologous
responder CD41 T cells and 104 dendritic cells loaded with
protein MAGE-3 as stimulator cells. IL-6 and IL-12 were
added during the first week to activate the T cells. The re-
sponder T cells received three additional weekly restimula-
tions with dendritic cells pulsed with protein MAGE-3 in
the presence of IL-2 and IL-7. After a resting period of 2
wk, the responder cells of each microculture were tested
on day 35 for TNF or, more often, for IFN-g production
after stimulation for 20 h with autologous EBV-B cells
loaded with protein MAGE-3.
CD41 T Cell Clones Directed against a MAGE-3 Antigen.
CD41 T cells of hemochromatosis patient LB 1555, stimu-
lated with dendritic cells loaded with protein MAGE-3,
were tested for their ability to produce TNF upon stimula-
tion with EBV-B cells loaded with either protein MAGE-3
or OVA. It was possible to measure the production of TNF
by the T cells because, contrary to most EBV-B cell lines,
that of patient LB 1555 did not produce TNF. The mi-
croculture (B6 in Fig. 2) that produced the highest level of
TNF after stimulation with protein MAGE-3 was cloned
by limiting dilution using autologous EBV-B cells loaded
with protein MAGE-3 as stimulator cells. These stimulator
cells were used for the cloning step because of the limited
supply of autologous dendritic cells. A positive CD41
clone was obtained, referred to hereafter as clone 37. It rec-
ognized autologous EBV-B cells loaded with protein
MAGE-3. Even though the protein, which had been pro-
duced in bacteria, was .95% pure, we could not at this
stage exclude the possibility that clone 37 recognized a bac-
terial contaminant. Therefore, we prepared a set of pep-
tides of 16 aa, which overlapped by 12 and covered the en-
tire MAGE-3 protein sequence. Each of these peptides was
incubated with autologous EBV-B cells and tested for rec-
ognition by clone 37. We identified two overlapping pep-
tides, MAGE-3111–126 and MAGE-3115–130 (see below), that
stimulated production of both TNF (data not shown) and
IFN-g (Fig. 3 A). This demonstrated unambiguously that
clone 37 recognized a MAGE-3 antigen and not a contam-
inant.
A CD41 clone was obtained from another microculture
which was also very well stimulated by cells loaded with
protein MAGE-3 (F3 in Fig. 2). However, here the screen-
ing with the set of overlapping MAGE-3 peptides was neg-
ative. We found that the antigen recognized by this CD41
clone was present in an HPLC fraction other than the one
containing the MAGE-3 protein (data not shown). Our
tentative conclusion is that this clone recognizes a bacterial
contaminant.
Additional CD41 clones were obtained from five inde-
pendent microcultures, set up with cells from another
hemochromatosis patient. Their ability to recognize cells
loaded with protein MAGE-3 appeared to decrease upon
further purification of the protein by HPLC. Two of these
clones were also tested for their response to the set of
MAGE-3 peptides, with negative results, suggesting further
that they recognized a contaminant in the MAGE-3 batch.
Therefore, it appears that bacterial contaminants in this
MAGE-3 protein batch were more likely to activate CD41
T cells than was MAGE-3 itself, so that CD41 clones spe-
cific for MAGE-3 constituted only a minor fraction of the
clones obtained with this procedure.
Figure 1. Overview of the procedure used to obtain anti–MAGE-3 CD41 T cell clones.771 Chaux et al.
Clone 37 Recognizes Peptide AELVHFLLLKYRAR on
HLA-DR13. CD41 clone 37 recognized two peptides
which overlapped by 12 aa, namely RKVAELVHFLL-
LKYRA (aa 111–126) and ELVHFLLLKYRAREPV (aa
115–130) (Fig. 3 A). The recognition by clone 37 of cells
loaded with protein MAGE-3 was abolished by an anti–
HLA-DR antibody (data not shown). Patient LB 1555 was
serologically typed DR3, DR13, and DR52. To identify
the presenting HLA-DR molecule, we tested additional
EBV-B cell lines expressing DR3, DR13, or DR52. All
and only those expressing DR13 were able to present the
MAGE-3111–126 and MAGE-3115–130 peptides to clone 37
(Table I). 31 different HLA-DR13 alleles have been de-
scribed to date (33). LB 1555 expresses the DRB1*1302
allele, and the other DR13 cell lines tested express DRB1*
1301 or DRB1*1302, the latter two representing 80% of
the HLA-DR13 alleles.
Unlike the peptides presented by class I molecules, those
presented by class II usually vary in length and tolerate ex-
tensions at both the NH2 and COOH termini because they
are not fixed by their ends in the groove (34). Therefore, it
is difficult to define the length of those peptides precisely.
We tested a large number of MAGE-3 peptides of different
lengths (data not shown) and concluded that the shortest
peptide well recognized by clone 37 is AELVHFLLLK-
YRAR (aa 114–127; Fig. 3 B). Half-maximum value of
stimulation was obtained by incubating the stimulator cells
with 10 nM of this peptide. This compares favorably with
the results obtained with other epitopes recognized on
HLA class II molecules by CD41 T cells: a minimum of 30
nM of a bcr-abl peptide was needed to induce a significant
proliferation of an anti–bcr-abl CD41 cell line, whereas
330 nM of peptide p21-ras was required for anti–p21-ras
CD41 clones (22, 23).
Figure 2. Production of TNF by CD41 T cells stimulated with autolo-
gous EBV-B cells incubated with protein MAGE-3. EBV-B cells from
hemochromatosis patient LB 1555 were incubated with 20 mg/ml of
OVA or MAGE-3 protein for 20 h. 5,000 cells were distributed in mi-
crowells to which an aliquot of each of the 96 CD4 microcultures was
added (z3,000 effector cells). TNF production was estimated after over-
night culture, by the toxicity of the supernatants for the TNF-sensitive
WEHI 164-13 cells. The dots represent the average result obtained with
two aliquots of each CD4 microculture.
Figure 3. MAGE-3 peptides
recognized by clone 37. (A) Stimu-
lation of clone 37 by two overlap-
ping MAGE-3 peptides. Autolo-
gous EBV-B cells were incubated
for 2 h with different concentra-
tions of the peptides. Clone 37
(2,500 cells) was then cocultured
with 5,000 peptide-pulsed cells for
20 h. IFN-g production in the su-
pernatant was measured by ELISA.
(B) Stimulation by the shortest
peptide recognized by clone 37.
Conditions were as in A.
Table I. HLA-DR13 Cells Present the Two Peptides
MAGE-3111–126 and MAGE-3115–130 to CD41 Clone 37
EBV-B
cell line
Serological
specificity
IFN-g production by clone 37
stimulated with peptide
MAGE-3111–126 MAGE-3115–130
DR13 positive pg/ml
LB 1555 DR31 DR521 .4,000 .4,000
LB 1118 DR31 DR521 3,761 3,909
LB 1622 DR32 DR521 1,731 1,349
OMW DR32 DR521 .4,000 .4,000
MZ2 DR32 DR522 3,429 3,096
DR13 negative
BM16 DR32 DR521 99 120
BOB DR32 DR521 128 101
BOLETH DR32 DR521 77 67
Autologous LB 1555 EBV or allogeneic EBV-B cells were incubated for
2 h with 5 mg/ml of peptides MAGE-3111–126 and MAGE-3115–130, and
washed. Clone 37 was then incubated for 20 h with 5,000 peptide-pulsed
EBV-B cells. IFN-g released in the supernatant was measured by ELISA.772 MAGE-3 Epitopes Presented by HLA Class II Molecules
Dendritic Cells Incubated with Cell Lysates Present the
MAGE-3 Antigen. We tested dendritic cells, incubated
with decreasing concentrations of MAGE-3 protein, for
their ability to stimulate clone 37 (Fig. 4 A). Half-maxi-
mum production of IFN-g was obtained when 104 den-
dritic cells were preincubated in a volume of 100 ml with
30 ng of the protein, which is approximately the amount
present in 2 3 104 MZ2-MEL.43 tumor cells (Godelaine,
D., personal communication). This suggested that a den-
dritic cell, having endocytosed debris of just one or a few
tumor cells expressing MAGE-3, would be capable of stim-
ulating anti–MAGE-3 CD41 T cells. To test further the
ability of dendritic cells to process debris of cells expressing
MAGE-3, 293-EBNA cells transiently transfected with the
MAGE-3 gene were lysed and incubated for 24 h with
HLA-DR13 dendritic cells. These cells stimulated clone 37
(Fig. 4 B). The amount of IFN-g released by clone 37 in-
creased with the amount of plasmid used for the transfection.
Presentation of the Antigen by Cells Expressing the Ii.
MAGE-3 Construct. A melanoma cell line which ex-
presses HLA-DR13 and MAGE-3 was unable to stimulate
the release of IFN-g by clone 37, unless it was pulsed with
the MAGE-3115–130 peptide (Fig. 5 A). This suggests that the
MAGE-3 protein synthesized endogenously does not reach
the class II presentation pathway. It has been reported that
signals within the Ii could be used to target endogenously
synthesized protein to the class II antigen-processing com-
partments. The expression of several constructs, which en-
coded fusion proteins containing part of the mouse Ii fol-
lowed by fragments of the OVA gene, generated OVA
peptides recognized by murine CD41 T cells on MHC
class II molecules. The highest level of antigen presentation
was obtained with a construct containing the sequence
coding for the first 80 amino acids of the Ii (35). Accord-
ingly, MZ2-MEL.43 cells were transduced with a retroviral
construct encoding the first 80 amino acids of the human Ii
fused with MAGE-3 (retro–Ii.MAGE-3). MZ2-MEL.43
cells transduced with retro–Ii.MAGE-3 stimulated a high
production of IFN-g by clone 37, indicating that the
Ii.MAGE-3 protein was processed through the class II pre-
sentation pathway (Fig. 5 A). HLA-DR13 EBV-B cells trans-
duced with the same construct also stimulated clone 37 (Fig.
5 B). In contrast, HLA-DR13 EBV-B cells transduced with
retro–MAGE-3 alone were unable to stimulate clone 37.
Two Other CD41 Clones Recognized a Neighboring MAGE-3
Peptide on HLA-DR13. CD41 T cells isolated from the
blood of melanoma patient 7002, who had been immu-
nized with the MAGE-3 protein, were stimulated with au-
tologous dendritic cells loaded with MAGE-3 protein. Af-
ter three restimulations, one microculture produced IFN-g
upon stimulation with autologous EBV-B cells loaded with
the protein. CD41 clone 2 was isolated, which produced
IFN-g upon stimulation with cells that were either loaded
with MAGE-3 protein or transduced with Ii.MAGE-3, the
latter proving that the clone was directed against MAGE-3
and not against a contaminant of the protein batch (Fig. 6 A).
Figure 4. Presentation of the MAGE-3 antigen by dendritic cells
incubated with purified protein or cell lysates. (A) HLA-DR13 den-
dritic cells were cultured for 24 h with different concentrations of
MAGE-3 protein. The cells were washed, then incubated with 2,500
cells per well of clone 37. IFN-g production was measured after 20 h
by ELISA. The results shown represent the average of triplicate cul-
tures. (B) 293-EBNA cells (5 3 105 cells per well) were transfected
with different doses of pCEP4-MAGE-3 mixed with Lipofectamine®.
24 h after transfection, the transfected cells were lysed by freeze–thaw-
ing. HLA-DR13 dendritic cells (105 cells per well) were cultured with
lysates at the equivalent of 5 293-EBNA cells per dendritic cell for
24 h. The experiment was pursued as in A.
Figure 5. Recognition by clone 37 of
cells expressing an Ii MAGE-3 construct.
(A) MZ2-MEL.43 melanoma cells express
both HLA-DR13 and MAGE-3. Cells were
pulsed for 2 h with 5 mg/ml of peptide
MAGE-3115–130 and washed, or transduced
with a retroviral construct encoding
Ii.MAGE-3. (B) MZ2-EBV cells express
HLA-DR13. As a positive control for stimu-
lating cells, we incubated them for 20 h with
20 mg/ml of protein MAGE-3. MZ2-EBV
cells were transduced with a retroviral
construct encoding MAGE-3 alone or
Ii.MAGE-3. Tumor cells (104) and EBV-B
cells (5 3 103) were distributed in micro-
wells, and 2,500 cells of clone 37 were added.
IFN-g production was measured after 20 h of
coculture by ELISA. The results shown rep-
resent the average of triplicate cultures.773 Chaux et al.
When the set of overlapping MAGE-3 peptides were
tested for recognition by clone 2, peptide ELVH-
FLLLKYRAREPV (aa 115–130) scored positive (Fig. 6 B).
This peptide was shown previously to be recognized by
clone 37, isolated from hemochromatosis patient LB 1555.
However, peptide FLLLKYRAREPVTKAE (aa 119–134)
scored positive with clone 2 but was not recognized by
clone 37 (Fig. 7 B). Moreover, peptide RKVAELVHFLL-
LKYRA (aa 111–126), previously shown to be recognized
by clone 37, was not recognized by clone 2. This indicated
clearly that clones 2 and 37 were directed against two adja-
cent but distinct epitopes. Several EBV-B cell lines were
tested for their ability to present peptide MAGE-3119–134 to
clone 2. All and only those expressing DR13 were capable
of presenting the peptide (Table II). Patient 7002 expresses
the DRB1*1302 allele. We tested a large number of
MAGE-3 peptides at different concentrations to identify
Figure 6. Clone 2 recognizes a different
MAGE-3 epitope than clone 37. (A) Pro-
duction of IFN-g by clone 2 stimulated
with autologous EBV-B cells incubated
with protein MAGE-3, or transduced with
a retroviral vector encoding the Ii.MAGE-3
fusion protein. Autologous EBV-B cells
were incubated for 20 h with 20 mg/ml of
the recombinant MAGE-3 protein. Clone 2
(2,500 cells) was incubated with 5,000 au-
tologous EBV-B cells loaded with MAGE-3,
or transduced with Ii.MAGE-3. IFN-g
production was measured after 20 h by
ELISA. The results shown represent the av-
erage of triplicate cultures. (B) HLA-DR13
EBV-B cells were incubated for 2 h with
different concentrations of overlapping
MAGE-3 peptides. The peptides were puri-
fied by HPLC, to compare accurately the
efficacy of the different peptides used at the
same concentrations. Clones (2,500 cells)
were incubated with 5,000 peptide-pulsed
cells for 20 h. IFN-g production was mea-
sured by ELISA. The results shown repre-
sent the average of triplicate cultures.
Figure 7. Stimulation of CD4
clone 2 by the MAGE-3121–134
peptide. HLA-DR13 EBV-B
cells were pulsed for 2 h with
different concentrations of the
peptide. Clones (2,500 cells)
were incubated with 5,000 pep-
tide-pulsed cells for 20 h. IFN-g
production was measured by
ELISA.
Table II. HLA-DR13 Cells Present Peptide MAGE-3119–134 to 
CD41 Clones 2 and 22
EBV-B cell line
Serological
specificity
IFN-g production after
stimulation with pep-
tide MAGE-3119–134 of
Clone 2 Clone 22
DR13 positive pg/ml
7002 DR11 DR521 .4,000 .4,000
LB 1158 DR11 DR521 .4,000 3,967
LB 1118 DR12 DR521 .4,000 1,345
LB 1622 DR12 DR521 3,993 1,250
OMW DR12 DR521 3,153 3,651
MZ2 DR11 DR522 .4,000 2,030
DR13 negative
LKT3 DR11 DR521 00
RSH DR11 DR521 00
BM16 DR12 DR521 12 7
EBV-B cells were incubated for 2 h with 1 mg/ml of peptide MAGE-
3119–134, and washed. Clones 2 and 22 were then incubated for 20 h
with 5,000 peptide-pulsed cells. IFN-g released in the supernatant was
measured by ELISA. Among the DR131 cells, some were DRB1*1301
and others were DRB1*1302.774 MAGE-3 Epitopes Presented by HLA Class II Molecules
the shortest peptide efficiently recognized by clone 2 (data
not shown). This proved to be LLKYRAREPVTKAE (aa
121–134; Fig. 7).
Interestingly, peptide MAGE-3121–134 is also present in
proteins MAGE-1, -2, and -6. Therefore, we loaded
DR13 EBV-B cells with a MAGE-1 recombinant protein
and used them to stimulate the CD41 clones. Clone 2, but
not clone 37, produced IFN-g (data not shown).
From hemochromatosis patient LB 1158, yet another
anti–MAGE-3 CD41 clone was obtained, referred to here-
after as clone 22. Patient LB 1158 expresses the DRB1*
1301 allele. Like clone 2, clone 22 was stimulated by DR13
cells presenting peptide MAGE-3119–134 (Table II) and did
not recognize peptide MAGE-3111–126 (data not shown). It
was also stimulated by DR13 cells loaded with the MAGE-1
protein (data not shown).
Discussion
The procedure described here seems efficient for the ac-
tivation of anti-MAGE CD41 precursors present in the
blood of individuals with or without cancer, and for the re-
sulting isolation of anti-MAGE CD41 permanent T cell
clones. We are quite confident that it will prove to be ap-
plicable to other proteins for the identification of new anti-
gens presented by HLA class II molecules. But our ap-
proach is not without disadvantages: a large number of the
CD41 clones obtained were apparently directed against
contaminants of the protein batch. Therefore, it will be
preferable to use one source of antigen for stimulation of
the T cells and another to test their specificity. This may be
achieved using two batches of protein produced in differ-
ent organisms, such as bacteria and insect cells infected with
baculovirus constructs, or, as shown here, by the use of
presenting cells expressing the protein of interest fused to a
truncated Ii.
Antigens can be processed through two different pathways
that lead to presentation on HLA class II molecules. The en-
dogenous pathway channels some proteins synthesized in the
cell towards endosomal compartments, where they are
cleaved into peptides that then associate with class II mole-
cules (36). In the exogenous pathway, the APC takes up
protein by endocytosis. Early endosomes undergo a progres-
sive transition to late endosomes and then to lysosomes. The
late endosomes have a relatively low pH, contain lysosomal
hydrolases, and are enriched in HLA-DM and MHC class II
molecules, which are associated with Ii in nonameric com-
plexes. Therefore, they are also called MHC class II com-
partments (MIIC). Ii is rapidly degraded but class II–associ-
ated Ii peptide (CLIP), a small part of it, remains bound
within the groove of the MHC molecule and blocks access
of other peptides until HLA-DM catalyzes its dissociation
from class II molecules. This permits the subsequent loading
of potentially antigenic peptides. The peptide–HLA class II
complexes are then directed to the cell surface (37).
Melanocyte-specific proteins such as tyrosinase contain a
lysosomal targeting sequence that enables them to follow
the endogenous class II processing pathway (38). There-
fore, these differentiation antigens can be recognized di-
rectly by CD41 T cells on those melanomas that express
class II molecules (39). Constitutive expression of class II
occurs frequently in melanoma. In line with their cytosolic
and nuclear localizations, the MAGE proteins appear to
lack the targeting sequences that would enable them to fol-
low the endogenous class II pathway (5, 40, 41). This
probably explains why the anti–MAGE-3 CD41 clones
obtained were unable to recognize an HLA-DR13 tumor
cell line expressing MAGE-3.
The anti–MAGE-3 CD41 clones could be stimulated by
HLA-DR13 dendritic cells loaded with extracts of cells
producing a large amount of MAGE-3 protein. However,
they failed to recognize dendritic cells incubated with ly-
sates of tumor cells expressing MAGE-3. This might be
due to a lower quantity of protein MAGE-3 in these tumor
cell extracts. However, this process may be more efficient
in vivo, where loading of dendritic cells with apoptotic
bodies from tumor cells might result in very efficient pre-
sentation of MAGE-3 epitopes (42). The notion that
MAGE-3 antigens can be presented to CD41 T cells in
vivo is supported by the observation that some cancer pa-
tients produce anti-MAGE antibodies (11, 43, 44). This is
probably due to destruction of some tumor cells followed
by uptake of the debris by macrophages or dendritic cells.
In a recently completed clinical trial, 25 tumor-bearing
HLA-A1 melanoma patients with advanced disease re-
ceived 3 subcutaneous injections of a MAGE-3 peptide
presented by HLA-A1 (45). Tumor regressions were ob-
served in seven patients, and three of these were complete.
No increase in anti-MAGE CTLs could be detected in the
blood of these patients, including those whose tumor re-
gressed. The regressions occurred very slowly, suggesting
that they may have been caused by a weak immune re-
sponse. A major limitation of such a class I peptide–based
approach might be that the CTLs elicited by the peptide
reach the tumor but fail to be restimulated properly at the
tumor site so that CTL amplification does not occur. This
could be due to the lack of help by tumor-specific CD41 T
cells. Vaccination strategies with MAGE-3 products may
benefit from the induction of anti–MAGE-3 CD41 T cells,
despite the fact that tumor cells that express both class II
molecules and MAGE-3 are unable to activate CD41 T
cells directly. Upon lysis of some tumor cells by a first CTL
attack, tumor debris could be processed by tumor-infiltrat-
ing APCs. Activated tumor-specific CD41 T cells located
around the tumor could then be restimulated by these cells.
These CD41 T lymphocytes might then favor the activa-
tion and proliferation of the effector CD81 T cells, pro-
voke the maturation of dendritic cells via CD40–CD40L
interactions, and mediate recruitment of additional im-
mune cells at the tumor sites (46–48). The resulting ampli-
fication of the immune response might then lead rapidly to
the complete destruction of the tumor mass. Immunization
with MAGE-3 peptides presented by class I and class II
molecules or with a purified protein may represent one
possibility for inducing both MAGE-3–specific CD41 and
CD81 T cells. Another possibility is the reinfusion into pa-775 Chaux et al.
tients of autologous APCs loaded with MAGE-3 peptides
binding to both HLA class I and class II molecules. This will
require the characterization of several epitopes to cope with
HLA restriction. Alternatively, autologous dendritic cells
could be infected with recombinant viruses encoding an
Ii.MAGE-3 fusion protein. Expression of Ii.MAGE-3 in
EBV-transformed B cells was shown to result not only in the
presentation of class II epitopes, but also in a very efficient
presentation of a class I epitope recognized by an anti–
MAGE-3.A1 CTL (Corthals, J., and K. Thielemans, manu-
script in preparation). Patients could also be immunized di-
rectly with recombinant viruses encoding Ii.MAGE-3.
A number of results obtained in mice support the impor-
tance of immunization against antigens presented by class II
molecules. Direct injection of a recombinant vaccinia en-
coding a human papilloma virus E7 protein linked to the
sorting signal of the lysosomal-associated membrane pro-
tein (LAMP-1) was very effective in inducing protective
immunity against a challenge with an E71 class II1 tumor.
In contrast, animals injected with a vaccinia coding for the
normal E7 protein were not protected (49). In another
mouse model, strong protection was achieved against
highly aggressive tumor cells lacking MHC class II expres-
sion through a single vaccination with a tumor-specific T
helper peptide encoded by the Moloney murine leukemia
virus (21). In this model, the CD81 CTLs were helped ef-
ficiently by peptide-primed tumor-specific CD41 T cells.
A clinical trial was recently initiated with a MAGE-3 re-
combinant protein. In this trial as in others involving re-
combinant viruses harboring large MAGE sequences, it
will be essential to have reliable monitoring of the anti–
MAGE-3 CD41 response. Our observations that CD41
cells directed against a minor contaminant in the protein
batch can easily be activated in vitro have implications for
this monitoring. To avoid possible misinterpretation of in
vitro assays and of delayed-type hypersensitivity (DTH) as-
says, a protein produced in another organism or autologous
cells expressing the antigen endogenously should be used
for these assays. Another possibility, which narrows the
analysis to certain epitopes, is the use of a set of relevant
peptides that can be used either to select and amplify pep-
tide-specific T cells in vitro or to label directly T cell re-
ceptors with soluble HLA tetramers presenting the relevant
peptide (50, 51). Multimeric soluble MHC class II mole-
cules, complexed with a peptide attached covalently, were
recently shown to bind with appropriate specificity and af-
finity to mouse-specific T cells (52). This approach requires
prior identification of the antigenic peptides, as described
in this report. Considering that several MAGE genes share
the sequence coding for one of the two MAGE-3.DR13
epitopes reported here, these peptides are relevant to
z16% of Caucasian melanoma patients, as 20% of Cauca-
sians express HLA-DR13 and z80% of metastatic melano-
mas express MAGE-1, -2, -3, or -6.
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